{"date":"2026-11-09","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4168-2026-11-09-0800-1ezdnqc","company_id":"4168","company":"醣聯","market":"上櫃","industry":"生技醫療","date":"2026-11-09","time":"08:00:41","subject":"本公司骨質疏鬆症生物相似藥SPD8（Denosumab）正式向日本PMDA提出製造販售承認申請","clause":"第53款","fact_date":"2026-11-09","cite_as":"公開資訊觀測站重大訊息：醣聯（4168），2026-11-09 08:00，「本公司骨質疏鬆症生物相似藥SPD8（Denosumab）正式向日本PMDA提出製造販售承認申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}